MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 471211 | Name: Ro 31-8425
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ro 31-8425 is a potent and selective inhibitor of protein kinase C (PKC), particularly targeting conventional and novel PKC isoforms. It exhibits nanomolar potency, with reported IC₅₀ values of approximately 6 nM for PKCα and 9 nM for PKCβ. Ro 31-8425 is cell-permeable and has been shown to effectively inhibit PKC-mediated phosphorylation events in cellular assays at concentrations around 100–300 nM. It displays minimal activity against other kinases such as PKA, PKG, or CAMKII at these concentrations, indicating high selectivity.

Chemical Structure

Ro 31-8425
Ro 31-8425
CAS#145317-11-9

Theoretical Analysis

MedKoo Cat#: 471211

Name: Ro 31-8425

CAS#: 145317-11-9

Chemical Formula: C26H25ClN4O2

Exact Mass: 0.0000

Molecular Weight: 460.96

Elemental Analysis: C, 67.75; H, 5.47; Cl, 7.69; N, 12.15; O, 6.94

Price and Availability

Size Price Availability Quantity
25mg USD 550.00 2 Weeks
50mg USD 950.00 2 Weeks
100mg USD 1,650.00 2 Weeks
1g USD 5,850.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Ro 31-8425; Ro31-8425; Ro-31-8425;
IUPAC/Chemical Name
3-(8-(aminomethyl)-6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione hydrochloride
InChi Key
IMBOYWXMTUUYGZ-UHFFFAOYSA-N
InChi Code
InChI=1S/C26H24N4O2.ClH/c1-29-14-18(16-6-2-4-8-19(16)29)23-24(26(32)28-25(23)31)22-17-7-3-5-9-20(17)30-11-10-15(13-27)12-21(22)30;/h2-9,14-15H,10-13,27H2,1H3,(H,28,31,32);1H
SMILES Code
O=C(C(C1=C(CC(CN)CC2)N2C3=C1C=CC=C3)=C4C5=CN(C)C6=C5C=CC=C6)NC4=O.[H]Cl
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
The compound has been used extensively in research to dissect PKC signaling pathways in various cell types, including immune cells, neurons, and cancer models, and has demonstrated anti-proliferative and anti-inflammatory effects in vitro.

Preparing Stock Solutions

The following data is based on the product molecular weight 460.96 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Sullivan JA, Merritt JE, Budd JM, Booth RF, Hallam TJ. Effect of a selective protein kinase C inhibitor, Ro 31-8425, on Mac-1 expression and adhesion of human neutrophils. Eur J Immunol. 1994 Mar;24(3):621-6. doi: 10.1002/eji.1830240320. PMID: 8125132. 2: Levy O, Rothhammer V, Mascanfroni I, Tong Z, Kuai R, De Biasio M, Wang Q, Majid T, Perrault C, Yeste A, Kenison JE, Safaee H, Musabeyezu J, Heinelt M, Milton Y, Kuang H, Lan H, Siders W, Multon MC, Rothblatt J, Massadeh S, Alaamery M, Alhasan AH, Quintana FJ, Karp JM. A cell-based drug delivery platform for treating central nervous system inflammation. J Mol Med (Berl). 2021 May;99(5):663-671. doi: 10.1007/s00109-020-02003-9. Epub 2021 Jan 4. PMID: 33398468; PMCID: PMC8292974. 3: Zou M, Xue Y. [Protective effect of protein kinase C inhibitor Ro-31-8425 on hyperpermeability of human umbilical vein endothelial cells exposed to high glucose in vitro]. Nan Fang Yi Ke Da Xue Xue Bao. 2012 Dec;32(12):1787-91. Chinese. PMID: 23268411. 4: Muid RE, Dale MM, Davis PD, Elliott LH, Hill CH, Kumar H, Lawton G, Twomey BM, Wadsworth J, Wilkinson SE, et al. A novel conformationally restricted protein kinase C inhibitor, Ro 31-8425, inhibits human neutrophil superoxide generation by soluble, particulate and post-receptor stimuli. FEBS Lett. 1991 Nov 18;293(1-2):169-72. doi: 10.1016/0014-5793(91)81178-b. PMID: 1660001. 5: Conroy LA, Merritt JE, Giafi CF, Lamont AG, Hallam TJ. Definition of early Ca2+ signals induced by anti-CD3 antibody in a human Jurkat T-cell line using a selective protein kinase C inhibitor, Ro 31-8425. Biochem Soc Trans. 1993 Nov;21(4):384S. doi: 10.1042/bst021384s. PMID: 8131961. 6: Merritt JE, Sullivan JA, Tse J, Wilkinson Se, Nixon JS. Different sensitivities of neutrophil responses to a selective protein kinase C inhibitor Ro 31-8425; redundancy in signal transduction. Cell Signal. 1997 Jan;9(1):53-7. doi: 10.1016/s0898-6568(96)00097-6. PMID: 9067630. 7: Levy O, Mortensen LJ, Boquet G, Tong Z, Perrault C, Benhamou B, Zhang J, Stratton T, Han E, Safaee H, Musabeyezu J, Yang Z, Multon MC, Rothblatt J, Deleuze JF, Lin CP, Karp JM. A small-molecule screen for enhanced homing of systemically infused cells. Cell Rep. 2015 Mar 3;10(8):1261-1268. doi: 10.1016/j.celrep.2015.01.057. Epub 2015 Feb 26. PMID: 25732817; PMCID: PMC4361231. 8: Ghosh AK. Regulation by prostaglandin E2 and histamine of angiogenesis in inflammatory granulation tissue. Yakugaku Zasshi. 2003 May;123(5):295-303. doi: 10.1248/yakushi.123.295. PMID: 12772586. 9: Matsumoto S, Yoshida S, Ikeda M, Tanimoto T, Saiki C, Takeda M, Shima Y, Ohta H. Effect of 8-bromo-cAMP on the tetrodotoxin-resistant sodium (Nav 1.8) current in small-diameter nodose ganglion neurons. Neuropharmacology. 2007 Mar;52(3):904-24. doi: 10.1016/j.neuropharm.2006.10.008. Epub 2006 Nov 29. PMID: 17140607. 10: Perez-Aso M, Segura V, Montó F, Barettino D, Noguera MA, Milligan G, D'Ocon P. The three α1-adrenoceptor subtypes show different spatio-temporal mechanisms of internalization and ERK1/2 phosphorylation. Biochim Biophys Acta. 2013 Oct;1833(10):2322-33. doi: 10.1016/j.bbamcr.2013.06.013. Epub 2013 Jun 21. PMID: 23797059. 11: Pozo D. Cell-based drug delivery harnesses inflammatory and autoimmune responses in neurodegeneration. J Mol Med (Berl). 2021 May;99(5):673-674. doi: 10.1007/s00109-021-02059-1. Epub 2021 Mar 8. PMID: 33683375; PMCID: PMC7938677. 12: Niu W, Bilan PJ, Yu J, Gao J, Boguslavsky S, Schertzer JD, Chu G, Yao Z, Klip A. PKCε regulates contraction-stimulated GLUT4 traffic in skeletal muscle cells. J Cell Physiol. 2011 Jan;226(1):173-80. doi: 10.1002/jcp.22320. PMID: 20658540. 13: Kamatchi GL, Tiwari SN, Chan CK, Chen D, Do SH, Durieux ME, Lynch C 3rd. Distinct regulation of expressed calcium channels 2.3 in Xenopus oocytes by direct or indirect activation of protein kinase C. Brain Res. 2003 Apr 11;968(2):227-37. doi: 10.1016/s0006-8993(03)02245-5. PMID: 12663092. 14: Chen MW, Zhu H, Xiong CH, Li JB, Zhao LX, Chen HZ, Qiu Y. PKC and Ras are Involved in M1 Muscarinic Receptor-Mediated Modulation of AMPA Receptor GluA1 Subunit. Cell Mol Neurobiol. 2020 May;40(4):547-554. doi: 10.1007/s10571-019-00752-x. Epub 2019 Nov 13. PMID: 31721013. 15: Hennenberg M, Strittmatter F, Walther S, Hedlund P, Andersson KE, Stief CG, Schlenker B, Gratzke C. α1-adrenoceptor activation induces phosphorylation of β2-adrenoceptors in human prostate tissue. BJU Int. 2011 Sep;108(6):922-8. doi: 10.1111/j.1464-410X.2010.10021.x. Epub 2011 Mar 4. PMID: 21371241. 16: Xia J, Ozaki I, Matsuhashi S, Kuwashiro T, Takahashi H, Anzai K, Mizuta T. Mechanisms of PKC-Mediated Enhancement of HIF-1α Activity and its Inhibition by Vitamin K2 in Hepatocellular Carcinoma Cells. Int J Mol Sci. 2019 Feb 26;20(5):1022. doi: 10.3390/ijms20051022. PMID: 30813635; PMCID: PMC6429062. 17: Harmon CS, Nevins TD, Ducote J, Lutz D. Bisindolylmaleimide protein-kinase-C inhibitors delay the decline in DNA synthesis in mouse hair follicle organ cultures. Skin Pharmacol. 1997;10(2):71-8. doi: 10.1159/000211471. PMID: 9257375. 18: Nixon JS, Bishop J, Bradshaw D, Davis PD, Hill CH, Elliott LH, Kumar H, Lawton G, Lewis EJ, Mulqueen M, et al. Novel, potent and selective inhibitors of protein kinase C show oral anti-inflammatory activity. Drugs Exp Clin Res. 1991;17(8):389-93. PMID: 1822831. 19: Nakashima M, Hamajima H, Xia J, Iwane S, Kwaguchi Y, Eguchi Y, Mizuta T, Fujimoto K, Ozaki I, Matsuhashi S. Regulation of tumor suppressor PDCD4 by novel protein kinase C isoforms. Biochim Biophys Acta. 2010 Sep;1803(9):1020-7. doi: 10.1016/j.bbamcr.2010.05.002. Epub 2010 May 12. PMID: 20471435. 20: Chellegatti MA, Yuvamoto PD, Said S. Role of phospholipase C and protein kinase C in Aspergillus nidulans during growth on pectin or glucose: Effects on germination and duplication cycle. Folia Microbiol (Praha). 2010 May;55(3):228-32. doi: 10.1007/s12223-010-0033-6. Epub 2010 Jun 6. PMID: 20526834.